KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Current Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Total Current Liabilities for 13 consecutive years, with $41.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 17.43% to $41.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.8 million through Dec 2025, up 17.43% year-over-year, with the annual reading at $41.8 million for FY2025, 17.43% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $41.8 million at Xenon Pharmaceuticals, up from $38.3 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $41.8 million in Q4 2025, with the low at $8.0 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $24.0 million, with a median of $23.7 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities plummeted 76.32% in 2021, then skyrocketed 181.77% in 2023.
  • Over 5 years, Total Current Liabilities stood at $14.3 million in 2021, then skyrocketed by 58.51% to $22.7 million in 2022, then increased by 20.13% to $27.3 million in 2023, then surged by 30.5% to $35.6 million in 2024, then grew by 17.43% to $41.8 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $41.8 million, $38.3 million, and $33.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.